Arrowhead Research Corporation (ARWR)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ARWR in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ARWR and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ARWR at a glance
Key statistics
$8.32B
Market capitalization
- Previous close
- $58.92
- Open
- $59.34
- Day range
- $59.31 – $60.36
- Volume
- 649.0K
- Average volume (30 sessions)
- 2.32M
- Shares outstanding
- 140.86M
- Earnings per share
- $(2.27)
- Price / book
- 17.9
- Price / sales
- 12.4
- Beta (1 year, vs SPY)
- 1.63
Where the price sits in its year
52-week range
39% of the range
- Below the 52-week high
- -37.3%
- Above the 52-week low
- +62.9%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $62.09-5.1%
- 50-day average
- $74.36-20.8%
- 200-day average
- $72.00-18.2%
Between the conventional 30 and 70 bands.
+1.4%
1 week
-14.3%
1 month
-33.6%
3 months
-11.3%
Year to date
+60.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ARWR
ARWR on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ARWR.
See the plans →
Every planScreen names like ARWR
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ARWR
Put ARWR on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ARWR
See whether there is an open premium alert on ARWR, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ARWR headlines
- Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Benzinga · Jan 6, 2026
- Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
Benzinga · Feb 7, 2024
- 4 Analysts Assess Arrowhead Pharma: What You Need To Know
Benzinga · Jan 2, 2024
- What 4 Analyst Ratings Have To Say About Arrowhead Pharma
Benzinga · Dec 4, 2023
- Analyst Expectations for Arrowhead Pharma's Future
Benzinga · Sep 19, 2023
- Analyst Ratings for Arrowhead Pharma
Benzinga · Aug 8, 2023
- Expert Ratings for Arrowhead Pharma
Benzinga · Jun 30, 2023
- Where Arrowhead Pharma Stands With Analysts
Benzinga · May 24, 2023
SEC Form 4, most recent first
Insider filings
OLUKOTUN ADEOYE Y
−2.0K
Director · Open-market sale
$173.92K · Aug 18, 2026
PERRY MICHAEL S
−11.6K
Director · Open-market sale
$1.01M · Aug 18, 2026
Cohen Matthew Gregory
+11.9K
Director · Grant or award
· Jun 15, 2026
Lu Hongbo
−3.0K
Director · Open-market sale
$228.33K · May 12, 2026
Apel Daniel Joseph
−3.2K
Chief Financial Officer · Open-market sale
$224.91K · Apr 22, 2026
Hamilton James C
−10.0K
Chief Medical Officer · Open-market sale
$750.00K · Apr 23, 2026
Apel Daniel Joseph
−1.2K
Chief Financial Officer · Open-market sale
$81.51K · Apr 22, 2026
Apel Daniel Joseph
−8.7K
Chief Financial Officer · Open-market sale
$627.86K · Apr 22, 2026
About Arrowhead Research Corporation
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Pasadena, CA
- Employees
- 711
- Listed since
- Feb 1, 1995
- Website
- arrowheadpharma.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.